The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global mRNA Cancer Vaccines and Therapeutics Market Research Report 2024
Synopsis
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
The global mRNA Cancer Vaccines and Therapeutics market was valued at US$ 140.4 million in 2023 and is anticipated to reach US$ 480.9 million by 2030, witnessing a CAGR of 19.0% during the forecast period 2024-2030.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.
Report Scope
The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global mRNA Cancer Vaccines and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Cancer Vaccines and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Segment by Application
Infectious Disease
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
The global mRNA Cancer Vaccines and Therapeutics market was valued at US$ 140.4 million in 2023 and is anticipated to reach US$ 480.9 million by 2030, witnessing a CAGR of 19.0% during the forecast period 2024-2030.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.
Report Scope
The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global mRNA Cancer Vaccines and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Cancer Vaccines and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Segment by Application
Infectious Disease
Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Adeno Carcinomas
1.2.3 Mucinous Carcinomas
1.2.4 Adenosquamous Carcinomas
1.3 Market by Application
1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global mRNA Cancer Vaccines and Therapeutics Market Perspective (2019-2030)
2.2 mRNA Cancer Vaccines and Therapeutics Growth Trends by Region
2.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 mRNA Cancer Vaccines and Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 mRNA Cancer Vaccines and Therapeutics Market Dynamics
2.3.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
2.3.2 mRNA Cancer Vaccines and Therapeutics Market Drivers
2.3.3 mRNA Cancer Vaccines and Therapeutics Market Challenges
2.3.4 mRNA Cancer Vaccines and Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue
3.1.1 Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue (2019-2024)
3.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by mRNA Cancer Vaccines and Therapeutics Revenue
3.4 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio
3.4.1 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by mRNA Cancer Vaccines and Therapeutics Revenue in 2023
3.5 mRNA Cancer Vaccines and Therapeutics Key Players Head office and Area Served
3.6 Key Players mRNA Cancer Vaccines and Therapeutics Product Solution and Service
3.7 Date of Enter into mRNA Cancer Vaccines and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Type
4.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Type (2025-2030)
5 mRNA Cancer Vaccines and Therapeutics Breakdown Data by Application
5.1 Global mRNA Cancer Vaccines and Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global mRNA Cancer Vaccines and Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America mRNA Cancer Vaccines and Therapeutics Market Size (2019-2030)
6.2 North America mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2019-2024)
6.4 North America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size (2019-2030)
7.2 Europe mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2019-2024)
7.4 Europe mRNA Cancer Vaccines and Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America mRNA Cancer Vaccines and Therapeutics Market Size (2019-2030)
9.2 Latin America mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2019-2024)
9.4 Latin America mRNA Cancer Vaccines and Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa mRNA Cancer Vaccines and Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Moderna Therapeutics
11.1.1 Moderna Therapeutics Company Detail
11.1.2 Moderna Therapeutics Business Overview
11.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
11.1.4 Moderna Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.1.5 Moderna Therapeutics Recent Development
11.2 CureVac
11.2.1 CureVac Company Detail
11.2.2 CureVac Business Overview
11.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Introduction
11.2.4 CureVac Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.2.5 CureVac Recent Development
11.3 Translate Bio
11.3.1 Translate Bio Company Detail
11.3.2 Translate Bio Business Overview
11.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Introduction
11.3.4 Translate Bio Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.3.5 Translate Bio Recent Development
11.4 BioNTech
11.4.1 BioNTech Company Detail
11.4.2 BioNTech Business Overview
11.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Introduction
11.4.4 BioNTech Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.4.5 BioNTech Recent Development
11.5 Sangamo Therapeutics
11.5.1 Sangamo Therapeutics Company Detail
11.5.2 Sangamo Therapeutics Business Overview
11.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
11.5.4 Sangamo Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.5.5 Sangamo Therapeutics Recent Development
11.6 Argos Therapeutics
11.6.1 Argos Therapeutics Company Detail
11.6.2 Argos Therapeutics Business Overview
11.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Introduction
11.6.4 Argos Therapeutics Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.6.5 Argos Therapeutics Recent Development
11.7 In-Cell-Art
11.7.1 In-Cell-Art Company Detail
11.7.2 In-Cell-Art Business Overview
11.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Introduction
11.7.4 In-Cell-Art Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.7.5 In-Cell-Art Recent Development
11.8 eTheRNA
11.8.1 eTheRNA Company Detail
11.8.2 eTheRNA Business Overview
11.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Introduction
11.8.4 eTheRNA Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.8.5 eTheRNA Recent Development
11.9 Ethris
11.9.1 Ethris Company Detail
11.9.2 Ethris Business Overview
11.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Introduction
11.9.4 Ethris Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.9.5 Ethris Recent Development
11.10 Tiba Biotechnology
11.10.1 Tiba Biotechnology Company Detail
11.10.2 Tiba Biotechnology Business Overview
11.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Introduction
11.10.4 Tiba Biotechnology Revenue in mRNA Cancer Vaccines and Therapeutics Business (2019-2024)
11.10.5 Tiba Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
